Ali Hassoun, MD
Infectious Disease · Huntsville, ALNPI 1063404978
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $194,833 of the $262,171 with a category attached, or 74.3%. 30 manufacturers reported payments, led by Pfizer at 30.5% of the total. Among infectious disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 672 payments — averaging $390.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$80K
- Ferring Pharmaceuticals Inc.$67K
- Astellas Pharma US Inc$40K
- Melinta Therapeutics, LLC$30K
- Cumberland Pharmaceuticals, Inc.$14K
- Tetraphase Pharmaceuticals, Inc.$9K
- plus $23K from 24 others
What the payments were for
- Consulting fees$25,66210%
- Speaking & faculty fees$194,83374%
- Travel & lodging$26,41910%
- Food & beverage$13,4265%
- Education$1,8311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $80,066 |
| Ferring Pharmaceuticals Inc. | 124 | $67,354 |
| Astellas Pharma US Inc | 86 | $39,626 |
| Melinta Therapeutics, LLC | 66 | $30,221 |
| Cumberland Pharmaceuticals, Inc. | 51 | $13,609 |
| Tetraphase Pharmaceuticals, Inc. | 15 | $8,506 |
| AbbVie(2 entities) | 90 | $6,601 |
| Merck | 43 | $5,414 |
| GSK | 4 | $3,291 |
| Shionogi Inc | 4 | $2,660 |
| La Jolla Pharmaceutical Company | 14 | $2,023 |
| Insmed, Inc. | 54 | $1,034 |
| Gilead | 18 | $396 |
| Viiv Healthcare Company | 20 | $363 |
| Theratechnologies Inc. | 11 | $211 |
| Aimmune Therapeutics, Inc. | 5 | $109 |
| Octapharma USA, Inc. | 1 | $95 |
| Dynavax Technologies Corporation | 5 | $86 |
| Cipla USA Inc. | 1 | $71 |
| Astellas Pharma Global Development | 1 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $62 |
| Grifols USA, LLC | 3 | $62 |
| Mayne Pharma Commercial LLC | 4 | $61 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $30 |
| AstraZeneca | 1 | $19 |
| Genentech, Inc. | 1 | $17 |
| Advanced Oxygen Therapy Inc. | 1 | $15 |
| T2 Biosystems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$262,171 in reported general payments places this provider in the 95th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 67 | $307,626 |
| Daptomycin | 387 | $197,374 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 44 | $167,672 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 36 | $138,197 |
| CresembaIsavuconazonium Sulfate | 23 | $125,772 |
| TeflaroCeftaroline Fosamil Acetate | 26 | $58,169 |
| Aztreonam | 80 | $41,416 |
| Cefepime Hcl | 217 | $40,417 |
| ErtapenemErtapenem Sodium | 39 | $19,837 |
| Epinephrine | 35 | $9,036 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 49 | $8,125 |
| Meropenem | 36 | $7,435 |
| CeftriaxoneCeftriaxone Sodium | 22 | $4,701 |
| Linezolid-D5wLinezolid In Dextrose 5% | 13 | $3,233 |
| Doxycycline Hyclate | 76 | $3,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Biktarvy | $396 | $445,823103 claims |
| Viiv Healthcare CompanyTriumeq | $363 | $167,67244 claims |
| Astellas Pharma US IncCresemba | $39,626 | $125,77223 claims |
| AbbVieTeflaro | $6,601 | $58,16926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 infectious disease providers in Alabama.
Other infectious disease in Huntsville
- Scott ParkerHuntsville$11K
- Hafsa SiddiquiHuntsville$5K
- Andres Gutierrez OrdonezHuntsville$2K
- Richard SperaHuntsville$2K
- Jordan Micah PolisticoHuntsville$1K
- Ingrid RoigHuntsville$646
- Tommy Parraga AcostaHuntsville$613
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Carlos Reyes-SacinMontgomery$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.